PropertyValue
?:abstract
  • Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19 While the specific effects of ruxolitinib on Janus kinases (JAK) is comparatively well investigated, its (unspecific) impact on membranes has not been studied in detail so far Therefore, we characterized the interaction of this drug with lipid membranes employing different biophysical approaches Ruxolitinib incorporates into the glycerol region of lipid membranes causing an increase in disorder of the lipid chains This binding, however, has only marginal influence on the structure and integrity of membranes as found by leakage and permeation assays
  • Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19. While the specific effects of ruxolitinib on Janus kinases (JAK) is comparatively well investigated, its (unspecific) impact on membranes has not been studied in detail so far. Therefore, we characterized the interaction of this drug with lipid membranes employing different biophysical approaches. Ruxolitinib incorporates into the glycerol region of lipid membranes causing an increase in disorder of the lipid chains. This binding, however, has only marginal influence on the structure and integrity of membranes as found by leakage and permeation assays.
is ?:annotates of
?:creator
?:journal
  • Biochem_Biophys_Rep
  • Biochemistry_and_Biophysics_Reports
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity
?:type
?:who_covidence_id
  • #1023478
  • #893615
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/7j9bpdey>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/7j9bpdey>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all